Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.45 |
| ▸ | USP14 | P54578 | 3/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL7230728 | 0.84 | HRH3 (0.44) | HRH3USP14USP7ALPLALPG | |
| SCHEMBL7230721 | 0.77 | USP14 (0.41) | HRH3USP14USP7ALPLALPG | |
| SCHEMBL6952914 | 0.75 | MAOB (0.50) | HRH3USP14USP7ALPLALPG | |
| Hydrochloric Acid SCHEMBL6957210 | 0.74 | MAOB (0.48) | HRH3USP14USP7ALPLALPG | |
| SCHEMBL7233635 | 0.73 | ADORA1 (0.46) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL26921088 | 0.72 | ALDH1A1 (0.62) | HRH3USP14USP7ALPLALPG | |
| SCHEMBL26921192 | 0.71 | ALDH1A1 (0.59) | HRH3USP14USP7ALPLALPG | |
| SCHEMBL7226430 | 0.67 | HTT (0.49) | HRH3USP14USP7ALPLALPG | |
| SCHEMBL9013246 | 0.67 | SIGMAR1 (0.46) | MCHR1 | |
| SCHEMBL13739264 | 0.67 | USP14 (0.50) | USP14USP7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6573267-B2 | Central nervous system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20020019436-A1 | Useful aroyl aminoacyl pyrrole compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2002002521-A2 | AROYL AMINOACYL PYRROLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019436-A1 | Useful aroyl aminoacyl pyrrole compounds | ABAT, GAP43, AADAT | HRH3 1152/4885USP14 3445/4885USP7 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.